Precipio (NASDAQ:PRPO) Stock Price Passes Below 200-Day Moving Average – Time to Sell?

Precipio, Inc. (NASDAQ:PRPO)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $25.07 and traded as low as $22.60. Precipio shares last traded at $22.60, with a volume of 246,846 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts have commented on PRPO shares. Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a research report on Friday, July 17th. Wall Street Zen cut shares of Precipio from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Precipio Stock Up 0.9%

The business’s 50 day moving average is $23.45 and its 200-day moving average is $25.05. The stock has a market cap of $40.35 million, a price-to-earnings ratio of -47.96 and a beta of 1.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.33 and a current ratio of 1.56.

Precipio (NASDAQ:PRPO) last posted its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.81) earnings per share for the quarter. The company had revenue of $6.71 million for the quarter. Precipio had a negative return on equity of 6.73% and a negative net margin of 3.57%.

Institutional Trading of Precipio

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in Precipio by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 789 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Precipio by 10.7% in the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 1,400 shares during the last quarter. Susquehanna International Group LLP purchased a new position in shares of Precipio in the third quarter worth about $194,000. Finally, BlackRock Inc. acquired a new position in Precipio during the second quarter worth about $858,000. 10.45% of the stock is currently owned by hedge funds and other institutional investors.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.